D
Enanta Pharmaceuticals, Inc. ENTA
$13.85 $0.010.07% NASDAQ
Recommendation
Dividend Power Score
Prev Close
$13.85
Volume
136,383
Avg Vol (90D)
342,815
Market Cap
$401.92M
Dividend & Yield
--
52-Week Range
$4.09 - $17.15
P/E (TTM)
--
EPS (TTM)
-$3.20
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock
2/12/2026 - Zacks Investment Research
Equities Analysts Issue Forecasts for ENTA Q2 Earnings
2/12/2026 - MarketBeat
Analysts Are Updating Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimates After Its First-Quarter Results
2/12/2026 - Simply Wall St
Enanta Pharmaceuticals (ENTA) Quarterly Loss Narrows Yet Keeps Profitability Concerns In Investor Focus
2/11/2026 - Simply Wall St
HC Wainwright Reaffirms "Buy" Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)
2/10/2026 - MarketBeat
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
2/10/2026 - Business Wire
Enanta Pharmaceuticals (ENTA, $13.86) price may drop as it broke higher Bollinger Band on Feb 09, 2026
2/10/2026 - Tickeron - Technical Analysis
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
2/9/2026 - Zacks Investment Research
Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Beats Estimates By $0.12 EPS
2/9/2026 - MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) Issues Quarterly Earnings Results, Beats Estimates By $0.12 EPS
2/9/2026 - Ticker Report
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
2/9/2026 - Business Wire
Enanta Pharmaceuticals (ENTA) Projected to Post Quarterly Earnings on Monday
2/2/2026 - MarketBeat
Enanta Pharmaceuticals (ENTA, $12.92) Aroon Indicator entered a Downtrend on January 29, 2026.
1/30/2026 - Tickeron - Stocks
Enanta Pharmaceuticals (ENTA, $12.65) Aroon Indicator entered a Downtrend on January 28, 2026.
1/29/2026 - Tickeron - Stocks
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
1/25/2026 - Ticker Report
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages
1/18/2026 - MarketBeat
Enanta Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
1/15/2026 - GuruFocus
Enanta Pharmaceuticals, Inc. (ENTA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
1/15/2026 - Seeking Alpha: Transcripts
Enanta Pharmaceuticals, Inc. (ENTA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
1/15/2026 - SeekingAlpha
Financial Contrast: Enanta Pharmaceuticals (NASDAQ:ENTA) & CytoDyn (OTCMKTS:CYDY)
1/12/2026 - Ticker Report
Enanta Pharmaceuticals (NASDAQ:ENTA) Receives "Buy" Rating from HC Wainwright
1/9/2026 - MarketBeat
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
1/8/2026 - GuruFocus
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
1/8/2026 - Business Wire
Enanta Pharmaceuticals (ENTA, $13.91) Aroon Indicator entered an Uptrend on January 05, 2026.
1/6/2026 - Tickeron - Stocks
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/5/2026 - GuruFocus
Income Statement
Total Revenue (TTM)
$66.98M
EBITDA (TTM)
-$68.13M
EBIT (TTM)
-$73.06M
Net Income (TTM)
-$71.54M
Balance Sheet
Total Assets (Q)
$329.50M
Total Debt (Q)
$193.18M
Total Liabilities (Q)
$202.91M
Book Value Per Share (Q)
$4.36
Cash Flow
Cash from Operations (TTM)
-$14.17M
Cash from Investing (TTM)
-$75.85M
Cash from Financing (TTM)
$42.50M
Net Change in Cash (TTM)
-$47.52M
Filings
Filing Date
Wednesday, February 11, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 11 and 15 (est)
Price History
Loading...
Beta
0.93
7-Day Total Return
6.78%
30-Day Total Return
-3.95%
60-Day Total Return
12.06%
90-Day Total Return
25.00%
Year to Date Total Return
-3.95%
1-Year Total Return
93.98%
2-Year Total Return
4.84%
3-Year Total Return
-72.17%
5-Year Total Return
-72.43%
52-week Low
Apr 09, 2025 - $4.09
52-week High
Dec 29, 2025 - $17.15
Valuation
Market Cap
$401.92M - Small Cap
Enterprise Value
$353.20M
Price/Sales (TTM)
5.94
Price/Book (Q)
3.17
Dividends and Shares
Shares Outstanding
28.75M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.enanta.com
Phone Number
617 607 0800
Address
4 Kingsbury Avenue
Watertown, MA 02472
Country
United States
Year Founded
1995
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which... more
NASDAQ 02/13/2026 4:00PM Eastern Quotes delayed